MET and neoplasm: As shown in Figure 6, in the high c-Met-amplified LU0858 model with Met copy number >14, ABN401 at 10 or 30 mg/kg as a single treatment demonstrated dose-related anti-tumor activity, with tumor growth inhibition (TGI) values of 68.6% and 84.9%, respectively.